When injected into mice harboring Her2-positive tumors, the AAV-Her2 efficiently targeted Her2+ cells and resulted in a more effective reduction in tumor mass than the clinical antibody control (Herceptin). This evidence concerns the gene ERBB2 and neoplasm.